Discovery of Potent and Non-cytotoxic HDAC3-Selective Degraders Featuring a Propyl Hydrazide Zinc-Binding Group
Journal of Medicinal Chemistry · 12.11.2026 · 69 (21) · 25256-25282
DOI: 10.1021/acs.jmedchem.6c01065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 24.10.2026. Verfasst von Stephan Lepper und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, 53121Bonn, Germany. Hauptthemen laut MEDLINE: Histone Deacetylases, Histone Deacetylase Inhibitors, Antineoplastic Agents, Zinc. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft, Deutscher AkademischerAustauschdienst, Deutscher Akademischer Austauschdienst.
Abstract (Originalsprache)
Histone deacetylase 3 (HDAC3) is an important therapeutic target in cancer, yet selective HDAC3 degraders remain limited. In this study, we report the development of novel class I HDAC degraders derived from the HDAC3-preferential inhibitor FL-007. Two linker exit vectors were investigated, leading to the identification of a series of potent compounds (2a−d) exhibiting low micromolar inhibition of HDAC2 and submicromolar inhibition of HDAC1 and HDAC3, together with selective HDAC3 degradation. Degradation activity was confirmed in MM.1S, HCT116, A2780-HDAC3-HiBiT, and Cal27CisR cells using immunoblotting and HiBiT/LgBiT assays, achieving Dmax values of up to 92%. Notably, these compounds showed no cytotoxicity up to 100 μM in both cancerous and non-cancerous cell lines. Selective HDAC3 degradation resulted in moderate chemosensitization of cisplatin-resistant Cal27CisR cells, in contrast to the stronger effects observed with cytotoxic HDAC inhibitors. For compound 2b, the chemosensitizing effect was associated with increased histone H3 acetylation and increased p21 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, 53121Bonn, Germany.
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University Duesseldorf, 40225Duesseldorf, Germany.
ORCID-Profile: Stephan Lepper, Lukas Biermann, Linda Schäker-Hübner, Matthias U Kassack, Finn K Hansen
Förderung
- Deutsche Forschungsgemeinschaft
- Deutscher AkademischerAustauschdienst
- Deutscher Akademischer Austauschdienst
Zitieren
APA
Lepper, S., Biermann, L., Kraft, F. B., Feller, F., Tan, K., Setia, N., Martens, E. C., Hamacher, A., Schäker-Hübner, L., Kassack, M. U., & Hansen, F. K. (2026). Discovery of Potent and Non-cytotoxic HDAC3-Selective Degraders Featuring a Propyl Hydrazide Zinc-Binding Group. Journal of Medicinal Chemistry, 69(21), 25256-25282. https://doi.org/10.1021/acs.jmedchem.6c01065
Vancouver
Lepper S, Biermann L, Kraft FB, Feller F, Tan K, Setia N, et al. Discovery of Potent and Non-cytotoxic HDAC3-Selective Degraders Featuring a Propyl Hydrazide Zinc-Binding Group. Journal of Medicinal Chemistry. 2026;69(21):25256-25282. doi:10.1021/acs.jmedchem.6c01065
BibTeX
@article{Lepper2026,
author = {Lepper, Stephan and Biermann, Lukas and Kraft, Fabian B and Feller, Felix and Tan, Kathrin and Setia, Nisha and Martens, Emma C and Hamacher, Alexandra and Schäker-Hübner, Linda and Kassack, Matthias U and Hansen, Finn K},
title = {Discovery of Potent and Non-cytotoxic HDAC3-Selective Degraders Featuring a Propyl Hydrazide Zinc-Binding Group},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {21},
pages = {25256--25282},
doi = {10.1021/acs.jmedchem.6c01065}
}
EUVIMED